Healthcare provider profile · identity verified

David Luo

Family Practice · STRATFORD, CT · NPI 1164957379

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	370	133
Lisinopril	Lisinopril	293	110
Gabapentin	Gabapentin	230	56
Levothyroxine Sodium	Levothyroxine Sodium	215	74
Omeprazole	Omeprazole	203	73
Amlodipine Besylate	Amlodipine Besylate	184	68
Losartan Potassium	Losartan Potassium	146	44
Albuterol Sulfate Hfa	Albuterol Sulfate	133	64
Montelukast Sodium	Montelukast Sodium	129	48
Furosemide	Furosemide	128	45
Sertraline Hcl	Sertraline Hcl	126	34
Metoprolol Succinate	Metoprolol Succinate	125	48
Rosuvastatin Calcium	Rosuvastatin Calcium	120	48
Simvastatin	Simvastatin	119	45
Pantoprazole Sodium	Pantoprazole Sodium	112	42
Fluticasone Propionate	Fluticasone Propionate	101	49
Metformin Hcl	Metformin Hcl	95	37
Azithromycin	Azithromycin	83	75
Metoprolol Tartrate	Metoprolol Tartrate	83	29
Potassium Chloride	Potassium Chloride	83	35
Tamsulosin Hcl	Tamsulosin Hcl	81	31
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	76	22
Allopurinol	Allopurinol	74	27
Oxycodone Hcl	Oxycodone Hcl	72	16
Duloxetine Hcl	Duloxetine Hcl	69	23
Trazodone Hcl	Trazodone Hcl	69	18
Lorazepam	Lorazepam	68	25
Jardiance	Empagliflozin	67	17
Tramadol Hcl	Tramadol Hcl	64	22
Hydrochlorothiazide	Hydrochlorothiazide	62	26
Ozempic	Semaglutide	62	13
Escitalopram Oxalate	Escitalopram Oxalate	61	24
Eliquis	Apixaban	60	20
Trulicity	Dulaglutide	59	13
Citalopram Hbr	Citalopram Hydrobromide	56	20
Famotidine	Famotidine	56	21
Meloxicam	Meloxicam	53	22
Quetiapine Fumarate	Quetiapine Fumarate	53	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	51	19
Tizanidine Hcl	Tizanidine Hcl	51	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	46	22
Diclofenac Sodium	Diclofenac Sodium	46	16
Warfarin Sodium	Warfarin Sodium	46	suppressed
Naproxen	Naproxen	44	18
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	43	43
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	42	12
Methylprednisolone	Methylprednisolone	42	39
Breo Ellipta	Fluticasone/Vilanterol	39	16
Xarelto	Rivaroxaban	39	suppressed
Cephalexin	Cephalexin	38	32
Prednisone	Prednisone	37	28
Doxycycline Monohydrate	Doxycycline Monohydrate	36	30
Venlafaxine Hcl Er	Venlafaxine Hcl	34	suppressed
Celecoxib	Celecoxib	33	17
Clopidogrel	Clopidogrel Bisulfate	33	15
Ezetimibe	Ezetimibe	33	13
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Glimepiride	Glimepiride	33	12
Amitriptyline Hcl	Amitriptyline Hcl	32	suppressed
Glipizide	Glipizide	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	22
Zolpidem Tartrate	Zolpidem Tartrate	31	suppressed
Finasteride	Finasteride	30	11
Carvedilol	Carvedilol	29	13
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	29	18
Ventolin Hfa	Albuterol Sulfate	28	11
Buspirone Hcl	Buspirone Hcl	26	suppressed
Mounjaro	Tirzepatide	26	suppressed
Metformin Hcl Er	Metformin Hcl	25	13
Torsemide	Torsemide	25	suppressed
Alprazolam	Alprazolam	24	11
Baclofen	Baclofen	24	suppressed
Glipizide Er	Glipizide	24	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Mupirocin	Mupirocin	19	16
Clotrimazole	Clotrimazole	18	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Atenolol	Atenolol	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Morphine Sulfate	Morphine Sulfate	17	suppressed
Morphine Sulfate Er	Morphine Sulfate	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	15
Chlorthalidone	Chlorthalidone	16	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	13
Combivent Respimat	Ipratropium/Albuterol Sulfate	15	suppressed
Levofloxacin	Levofloxacin	15	12
Meclizine Hcl	Meclizine Hcl	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Fentanyl	Fentanyl	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	12	suppressed
Clonazepam	Clonazepam	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error